Scutt_et_al_TADS_Supplementary_material – Supplemental material for Does the 5-HT1A rs6295 polymorphism influence the safety and efficacy of citalopram therapy in the oldest old?

Scutt, Greg; Overall, Andrew; Scott, Railton; Patel, Bhavik; Hachoumi, Lamia; Yeoman, Mark; Wright, Juliet

doi:10.25384/SAGE.6242117.v1

Scutt_et_al_TADS_Supplementary_material.pdf (127.03 kB)

Scutt_et_al_TADS_Supplementary_material – Supplemental material for Does the 5-HT_1A rs6295 polymorphism influence the safety and efficacy of citalopram therapy in the oldest old?

journal contribution

posted on 2018-04-23, 12:00 authored by Greg Scutt, Andrew Overall, Railton Scott, Bhavik Patel, Lamia Hachoumi, Mark Yeoman, Juliet Wright

Supplemental material, Scutt_et_al_TADS_Supplementary_material for Does the 5-HT_1A rs6295 polymorphism influence the safety and efficacy of citalopram therapy in the oldest old? by Greg Scutt, Andrew Overall, Railton Scott, Bhavik Patel, Lamia Hachoumi, Mark Yeoman and Juliet Wright in Therapeutic Advances in Drug Safety

Funding

National Institute for Health Research

History

Usage metrics

Keywords

ageing Bayesian analysis depression pharmacogenomics

Licence

In Copyright

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC